Changes in circulating lipids level over time after acquiring HCV infection: Results from ERCHIVES

BMC Infectious Diseases

Volumn 15, Issue 1, 2015, Pages

  Butt, Adeel A ^a,b,c,d   Yan, Peng ^a   Simon, Tracey G ^e   Chung, Raymond T ^e   Abou Samra, Abdul Badi ^d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Hamad Healthcare Quality Institute   (Qatar)

^d HAMAD MEDICAL CORPORATION   (Qatar)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cholesterol; ERCHIVES; HCV; LDL; Lipid; Seroconversion

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN;

ADULT; ALCOHOL ABUSE; ALCOHOLISM; ARTICLE; BLACK PERSON; BODY MASS; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG ABUSE; DRUG DEPENDENCE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HISPANIC; HUMAN; HYPERTENSION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONHUMAN; SEROCONVERSION; BLOOD; CASE CONTROL STUDY; LIPID METABOLISM; LIVER CIRRHOSIS; METABOLISM;

ADULT; CASE-CONTROL STUDIES; CHOLESTEROL; CHOLESTEROL, HDL; FEMALE; HEPATITIS C; HUMANS; LIPID METABOLISM; LIPIDS; LIPOPROTEINS; LIPOPROTEINS, LDL; LIVER CIRRHOSIS; MALE; MIDDLE AGED; TRIGLYCERIDES;

EID: 84947867706     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-015-1268-2     Document Type: Article

References (33)

1. Butt AA, Wang X, Budoff M, Leaf DA, Kuller LH, Justice AC. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis. 2009;49:225-32.
2. Dai CY, Yeh ML, Huang CF, Hou CH, Hsieh MY, Huang JF, et al. Chronic hepatitis C infection is associated with insulin resistance and lipid profiles. J Gastroenterol Hepatol. 2013;10.
3. Siagris D, Christofidou, M, Theocharis GJ, Pagoni N, Papadimitriou C, Lekkou A, et al. Serum lipid pattern in chronic hepatitis C: histological and virological correlations. J Viral Hepat. 2006;13:56-61.
4. Forrester JE, McGovern BH, Rhee MS, Sterling RK. The individual and combined influence of HIV and hepatitis C virus on dyslipidaemia in a high-risk Hispanic population. HIV Med. 2009;10:555-63.
5. Chang ML, Tsou YK, Hu TH, Lin CH, Lin WR, Sung CM, et al. Distinct Patterns of the Lipid Alterations between Genotype 1 and 2 Chronic Hepatitis C Patients after Viral Clearance. PLoS One. 2014;9:e104783.
6. Jung HJ, Kim YS, Kim SG, Lee YN, Jeong SW, Jang JY, et al. The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients. Clin Mol Hepatol. 2014;20:38-46.
7. Aizawa Y, Shimada N, Abe H, Seki N, Aida Y, Ishiguro H, et al. Serum lipoprotein profiles and response to pegylated interferon plus ribavirin combination therapy in patients with chronic HCV genotype 1b infection. Hepat Mon. 2013;13:e8988.
8. Lange CM, Von WM, Bojunga J, Berg T, Farnik H, Hassler A, et al. Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-alpha-2a and ribavirin. Eur J Gastroenterol Hepatol. 2010;22:1303-7.
9. Butt AA, Yan P, Lo Re III V, Rimland D, Goetz MB, Leaf DA, et al. Liver fibrosis progression in hepatitis C virus infection after seroconversion. JAMA Intern Med. 2015;175:178-85.
10. Butt AA, Justice AC, Skanderson M, Good CB, Kwoh CK. Rates and predictors of HCV treatment in HCV-HIV coinfected persons. Aliment Pharmacol Ther. 2006;24:585-91.
11. Butt AA, Justice AC, Skanderson M, Rigsby M, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut. 2007;56:385-9.
12. Butt AA, Khan UA, McGinnis KA, Skanderson M, Kwoh CK. Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans. J Viral Hepat. 2007;14:890-6.
13. Butt AA, Wang X, Moore CM. Effect of HCV and its treatment upon survival. Hepatology. 2009;50:387-92.
14. Butt AA, McGinnis KA, Skanderson M, Justice AC. Hepatitis C treatment completion rates in routine clinical care. Liver Int. 2009;30:240-50.
15. Butt AA, Wang X, Fried LF. HCV infection and the incidence of chronic kidney disease. Am J Kid Dis. 2011;57:396-402.
16. Butt AA, McGinnis KA, Skanderson M, Justice AC. A comparison of treatment eligibility for HCV in HCV monoinfected vs. HCV/HIV coinfected persons in ERCHIVES (electronically retrieved cohort of HCV infected veterans). AIDS Res Hum Retroviruses. 2011;27:973-9.
17. Erqou S, Mohanty A, McGinnis KA, Vanasse G, Freiberg MS, Sherman KE, et al. Hepatitis C virus treatment and survival in patients with hepatitis C and human immunodeficiency virus co-infection and baseline anaemia. J Viral Hepat. 2013;20:463-9.
18. Mohanty A, Erqou S, McGinnis KA, Vanasse G, Freiberg MS, Sherman KE, et al. Therapy for hepatitis C virus infection increases survival of patients with pretreatment anemia. Clin Gastroenterol Hepatol. 2013;11:741-7.
19. Lambert JE, Bain VG, Ryan EA, Thomson AB, Clandinin MT. Elevated lipogenesis and diminished cholesterol synthesis in patients with hepatitis C viral infection compared to healthy humans. Hepatology. 2013;57:1697-704.
20. Fabris C, Federico E, Soardo G, Falleti E, Pirisi M. Blood lipids of patients with chronic hepatitis: differences related to viral etiology. Clin Chim Acta. 1997;261:159-65.
21. Marzouk D, Sass J, Bakr I, El HM, bdel-Hamid M, Rekacewicz C, et al. Metabolic and cardiovascular risk profiles and hepatitis C virus infection in rural Egypt. Gut. 2007;56:1105-10.
22. Dai CY, Chuang WL, Ho CK, Hsieh MY, Huang JF, Lee LP, et al. Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. J Hepatol. 2008;49:9-16.
23. Corey KE, Mendez-Navarro J, Barlow LL, Patwardhan V, Zheng H, Kim AY, et al. Acute hepatitis C infection lowers serum lipid levels. J Viral Hepat. 2011;18:e366-71.
24. Corey KE, Kane E, Munroe C, Barlow LL, Zheng H, Chung RT. Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology. 2009;50:1030-7.
25. Kim SS, Peng LF, Lin W, Choe WH, Sakamoto N, Kato N, et al. A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication. Gastroenterology. 2007;132:311-20.
26. Oem JK, Jackel-Cram C, Li YP, Zhou Y, Zhong J, Shimano H, et al. Activation of sterol regulatory element-binding protein 1c and fatty acid synthase transcription by hepatitis C virus non-structural protein 2. J Gen Virol. 2008;89:1225-30.
27. Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, Thimme R, et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A. 2002;99:15669-74.
28. Schaefer EA, Chung RT. HCV and host lipids: an intimate connection. Semin Liver Dis. 2013;33:358-68.
29. Mirandola S, Realdon S, Iqbal J, Gerotto M, Dal PF, Bortoletto G, et al. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology. 2006;130:1661-9.
30. Kanwal F, Kramer JR, Ilyas J, Duan Z, El-Serag HB. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology. 2014;60:98-105.
31. Tsochatzis E, Manolakopoulos S, Papatheodoridis GV, Hadziyannis E, Triantos C, Zisimopoulos K, et al. Serum HCV RNA levels and HCV genotype do not affect insulin resistance in nondiabetic patients with chronic hepatitis C: a multicentre study. Aliment Pharmacol Ther. 2009;30:947-54.
32. Milner KL, Van Der PD, Trenell M, Jenkins AB, Xu A, Smythe G, et al. Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology. 2010;138:932-41.
33. Duseja A, Dhiman RK, Chawla Y, Thumburu KK, Kumar A, Das A, et al. Insulin resistance is common in patients with predominantly genotype 3 chronic hepatitis C. Dig Dis Sci. 2009;54:1778-82.